TJ DaRenTang USD（T14）年次報告書

In the 1950s, with the China government's policy of merging state-owned

pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese

Medicinal Materials Corpn (TMCM) merged and reorganised the various factories

and stores in Tianjin. In December 1992, TMCM was converted from a state-owned

enterprise to a company limited by shares whereby shares were issued to legal

persons and its employees. In connection therewith, it was renamed Tianjin

Traditional Chinese Medicine Group Co Ltd (TTCM). Following the

corporatisation of the Company, the shares issued to the employees were traded

at the Tianjin Securities Trading Centre.

In conjunction with the proposed public offering, TTCM adopted its present

name. Pursuant to the restructuring, it became the holding company for the

Group.

The Group's businesses cover a wide range of products including Chinese patent

medicine, Chinese medicinal drinks, Chinese medicinal raw materials,

biotechnology medicine, chemical raw material medicine and preparations, and

nutritional and health products. It has over 800 medicinal products in over 20

types of formulations. The main products are Suxiao Jiuxin pill (used for

treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment

of intestines and stomach disease), Gengnian An (used for treatment of

menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu

Zhuyu capsule (used for treatment of diseases relating to heart and head blood

vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b

Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of

diabetes), and Te Zi She Fu (used for diminishing inflammation).

The holding company and ultimate holding company is Tianjin Pharmaceutical

Hldgs, a company incorporated in Tianjin, China.